« Back to news listing

Sorin Group Announces U.S. Launch of New Heart Device for Simultaneous Implantation

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the U.S. commercial launch of the Mitroflow Valsalva ConduitTM, the only Valsalva conduit graft approved by the U.S. Food and Drug Administration (FDA) for use in combination with an aortic tissue valve.

Read entire article: http://www.heraldonline.com/2012/11/06/4391283/sorin-group-announces-us-launch.html

« Back to news listing